These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29097141)

  • 1. Self-assembled nanocomplex of PEGylated protamine and heparin-suramin conjugate for accumulation at the tumor site.
    Park J; Hwang SR; Choi JU; Alam F; Byun Y
    Int J Pharm; 2018 Jan; 535(1-2):38-46. PubMed ID: 29097141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy.
    Alam F; Al-Hilal TA; Chung SW; Park J; Mahmud F; Seo D; Kim HS; Lee DS; Byun Y
    J Control Release; 2015 Jan; 197():180-9. PubMed ID: 25445701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical Conjugate of Low Molecular Weight Heparin and Suramin Fragment Inhibits Tumor Growth Possibly by Blocking VEGF165.
    Park J; Kim JY; Hwang SR; Mahmud F; Byun Y
    Mol Pharm; 2015 Nov; 12(11):3935-42. PubMed ID: 26448404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual mechanistic TRAIL nanocarrier based on PEGylated heparin taurocholate and protamine which exerts both pro-apoptotic and anti-angiogenic effects.
    Choi JU; Kim JY; Chung SW; Lee NK; Park J; Kweon S; Cho YS; Kim HR; Lim SM; Park JW; Lee KC; Byun Y
    J Control Release; 2021 Aug; 336():181-191. PubMed ID: 34144107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carrier-Enhanced Anticancer Efficacy of Sunitinib-Loaded Green Tea-Based Micellar Nanocomplex beyond Tumor-Targeted Delivery.
    Yongvongsoontorn N; Chung JE; Gao SJ; Bae KH; Yamashita A; Tan MH; Ying JY; Kurisawa M
    ACS Nano; 2019 Jul; 13(7):7591-7602. PubMed ID: 31262169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation.
    Chang LC; Lee HF; Chung MJ; Yang VC
    Bioconjug Chem; 2005; 16(1):147-55. PubMed ID: 15656586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversibly PEGylated nanocarrier for cisplatin delivery.
    Stoyanova E; Mitova V; Shestakova P; Kowalczuk A; Momekov G; Momekova D; Marcinkowski A; Koseva N
    J Inorg Biochem; 2013 Mar; 120():54-62. PubMed ID: 23318287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro assessment of a novel polyrotaxane-based drug delivery system integrated with a cell-penetrating peptide.
    Moon C; Kwon YM; Lee WK; Park YJ; Yang VC
    J Control Release; 2007 Dec; 124(1-2):43-50. PubMed ID: 17904680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced graphene oxide nanosheets coated with an anti-angiogenic anticancer low-molecular-weight heparin derivative for delivery of anticancer drugs.
    Shim G; Kim JY; Han J; Chung SW; Lee S; Byun Y; Oh YK
    J Control Release; 2014 Sep; 189():80-9. PubMed ID: 24973719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel size-tunable nanocarrier system for targeted anticancer drug delivery.
    Li Y; Xiao K; Luo J; Lee J; Pan S; Lam KS
    J Control Release; 2010 Jun; 144(3):314-23. PubMed ID: 20211210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxystress inducing antitumor therapeutics via tumor-targeted delivery of PEG-conjugated D-amino acid oxidase.
    Fang J; Deng D; Nakamura H; Akuta T; Qin H; Iyer AK; Greish K; Maeda H
    Int J Cancer; 2008 Mar; 122(5):1135-44. PubMed ID: 17990314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo.
    Lu J; Chuan X; Zhang H; Dai W; Wang X; Wang X; Zhang Q
    Int J Pharm; 2014 Aug; 471(1-2):525-35. PubMed ID: 24858391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced anti-angiogenesis and anti-tumor activity of endostatin by chemical modification with polyethylene glycol and low molecular weight heparin.
    Tan H; Yang S; Liu C; Cao J; Mu G; Wang F
    Biomed Pharmacother; 2012 Dec; 66(8):648-54. PubMed ID: 23122594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complexes of a modified low-molecular-weight heparin with protamine are predominantly cleared by a macrophage scavenger receptor-mediated process in rats.
    Stehle G; Wunder A; Sinn H; Schrenk HH; Friedrich EA; Dempfle CE; Maier-Borst W; Heene DL
    J Surg Res; 1995 Feb; 58(2):197-204. PubMed ID: 7861773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles.
    Hong M; Zhu S; Jiang Y; Tang G; Sun C; Fang C; Shi B; Pei Y
    J Control Release; 2010 Jan; 141(1):22-9. PubMed ID: 19735683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and characterization of self-assembled nanoparticles based on low-molecular-weight heparin and stearylamine conjugates for controlled delivery of docetaxel.
    Kim DH; Termsarasab U; Cho HJ; Yoon IS; Lee JY; Moon HT; Kim DD
    Int J Nanomedicine; 2014; 9():5711-27. PubMed ID: 25525355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo.
    Han HS; Lee J; Kim HR; Chae SY; Kim M; Saravanakumar G; Yoon HY; You DG; Ko H; Kim K; Kwon IC; Park JC; Park JH
    J Control Release; 2013 Jun; 168(2):105-14. PubMed ID: 23474029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
    Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
    Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bio-inspired drug-dominated supramolecular nanocomplex based on low molecular weight heparin for progressive tumor therapy.
    Yu Y; Xu C; Zhen L; Yang S; Zhou J; Yao J
    Carbohydr Polym; 2019 Sep; 220():30-42. PubMed ID: 31196548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and characterization of low-molecular-weight heparin/protamine nanoparticles (LMW-H/P NPs) as FGF-2 carrier.
    Mori Y; Nakamura S; Kishimoto S; Kawakami M; Suzuki S; Matsui T; Ishihara M
    Int J Nanomedicine; 2010 Apr; 5():147-55. PubMed ID: 20463930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.